DBV Technologies | DBVT - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amarin USD 3K 5K 2024-12
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
DBV Technologies USD 461K 323.71K 2025-03
Galectin Therapeutics USD 1.27M 220K 2024-06
Halozyme Therapeutics USD 5.59M 80K 2026-06
Incyte USD 582K 13K 2026-06
Insmed USD 18.84M 1.24M 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
PTC Therapeutics USD 3.25B 381.37M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
United Therapeutics USD 2.9M 200K 2026-06